Breast Cancer Research and Treatment

, Volume 158, Issue 3, pp 433–440 | Cite as

Evaluation of an amplicon-based next-generation sequencing panel for detection of BRCA1 and BRCA2 genetic variants

Preclinical study


The recent advances in the next-generation sequencing (NGS) technology have enabled fast, accurate, and cost-effective genetic testing. Here, we evaluated the performance of a targeted NGS panel for BRCA1/2 sequencing and confirmed its applicability in routine clinical diagnostics. We tested samples from 88 patients using the TruSeq custom panel (Illumina Inc, USA) and a MiSeq sequencer (Illumina) and compared the results to the outcomes of conventional Sanger sequencing. All 1015 sequence variations identified by Sanger sequencing were detected by NGS, except for one missense variant that might have been missed due to a rare mutation on a primer-binding site. One deletion variation, c.1909 + 12delT of BRCA2, was falsely called in all samples due to a homopolymer error. In addition, seven different single-nucleotide substitutions with low variant frequencies (range: 16.2–33.3 %) were falsely called by NGS. In a separate batch, 10 different false-positive variations were found in five samples. The overall sensitivity and positive predictive value of NGS were estimated to be 99.9 and 87.5 %, respectively. The false-positive results could be excluded by setting quality and alternative allele ratio filters and/or by visual inspection using the IGV software. Targeted NGS panel for BRCA1 and BRCA2 showed an excellent agreement with Sanger sequencing results. We therefore conclude that this NGS panel can be used for routine diagnostic method in a clinical genetic laboratory.


Next-generation sequencing BRCA1 BRCA2 TruSeq MiSeq Targeted sequencing 



This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A1A2043879), and by a grant from the National Research Foundation of Korea (NRF-2015R1C1A2A01055967).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68–78CrossRefGoogle Scholar
  2. 2.
    Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901CrossRefPubMedGoogle Scholar
  3. 3.
    D’Argenio V, Esposito MV, Telese A, Precone V, Starnone F, Nunziato M, Cantiello P, Iorio M, Evangelista E, D’Aiuto M et al (2015) The molecular analysis of BRCA1 and BRCA2: next-generation sequencing supersedes conventional approaches. Clin Chim Acta 446:221–225CrossRefPubMedGoogle Scholar
  4. 4.
    Metzker ML (2010) Sequencing technologies—the next generation. Nat Rev Genet 11(1):31–46CrossRefPubMedGoogle Scholar
  5. 5.
    Ruiz A, Llort G, Yague C, Baena N (2014) Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing. Biomed Res Int 2014:542541PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sikkema-Raddatz B, Johansson LF, de Boer EN, Almomani R, Boven LG, van den Berg MP, van Spaendonck-Zwarts KY, van Tintelen JP, Sijmons RH, Jongbloed JD et al (2013) Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 34(7):1035–1042CrossRefPubMedGoogle Scholar
  7. 7.
    Chan M, Ji SM, Yeo ZX, Gan L, Yap E, Yap YS, Ng R, Tan PH, Ho GH, Ang P et al (2012) Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform. J Mol Diagn 14(6):602–612CrossRefPubMedGoogle Scholar
  8. 8.
    Michils G, Hollants S, Dehaspe L, Van Houdt J, Bidet Y, Uhrhammer N, Bignon YJ, Vermeesch JR, Cuppens H, Matthijs G (2012) Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J Mol Diagn 14(6):623–630CrossRefPubMedGoogle Scholar
  9. 9.
    Bosdet IE, Docking TR, Butterfield YS, Mungall AJ, Zeng T, Coope RJ, Yorida E, Chow K, Bala M, Young SS et al (2013) A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations. J Mol Diagn 15(6):796–809CrossRefPubMedGoogle Scholar
  10. 10.
    Feliubadalo L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, Tornero E, Montes E, Cuesta R, Gomez C, Campos O et al (2013) Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet 21(8):864–870CrossRefPubMedGoogle Scholar
  11. 11.
    Yeo ZX, Wong JC, Rozen SG, Lee AS (2014) Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes. BMC Genom 15:516CrossRefGoogle Scholar
  12. 12.
    Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, Ostrowski J (2015) New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics 8:19CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M (2015) Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 3(2):121–129CrossRefPubMedGoogle Scholar
  14. 14.
    Trujillano D, Weiss ME, Schneider J, Koster J, Papachristos EB, Saviouk V, Zakharkina T, Nahavandi N, Kovacevic L, Rolfs A (2015) Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. J Mol Diagn 17(2):162–170CrossRefPubMedGoogle Scholar
  15. 15.
    Bragg LM, Stone G, Butler MK, Hugenholtz P, Tyson GW (2013) Shining a light on dark sequencing: characterising errors in ion torrent PGM data. PLoS Comput Biol 9(4):e1003031CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Meldrum C, Doyle MA, Tothill RW (2011) Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 32(4):177–195PubMedPubMedCentralGoogle Scholar
  17. 17.
    Mertes F, Elsharawy A, Sauer S, van Helvoort JM, van der Zaag PJ, Franke A, Nilsson M, Lehrach H, Brookes AJ (2011) Targeted enrichment of genomic DNA regions for next-generation sequencing. Brief Funct Genomics 10(6):374–386CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Morgan JE, Carr IM, Sheridan E, Chu CE, Hayward B, Camm N, Lindsay HA, Mattocks CJ, Markham AF, Bonthron DT et al (2010) Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat 31(4):484–491CrossRefPubMedGoogle Scholar
  19. 19.
    Mullins FM, Dietz L, Lay M, Zehnder JL, Ford J, Chun N, Schrijver I (2007) Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med 9(11):752–760CrossRefPubMedGoogle Scholar
  20. 20.
    Gray PN, Dunlop CL, Elliott AM (2015) Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel) 7(3):1313–1332CrossRefGoogle Scholar
  21. 21.
    Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y (2012) A tale of three next generation sequencing platforms: comparison of Ion Torrent, pacific biosciences and illumina miseq sequencers. BMC Genom 13:341CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Laboratory MedicineHallym University College of MedicineSeoulKorea
  2. 2.Brain Korea 21 PLUS Project for Medical ScienceYonsei UniversitySeoulKorea
  3. 3.Department of Laboratory MedicineYonsei University College of MedicineSeoulKorea

Personalised recommendations